Zydus Lifesciences

    ZYDUSLIFE
    Pharma
    ₹1099.00
    price as of 15/9/2026, 6:27:56 pm

    Market cap ₹1.10 L Cr

    P/E
    24.49
    Day range
    ₹1,099.00 – ₹1,124.50
    52-week range
    ₹835.50 – ₹1,205.00
    Volume
    5.22 L
    Open
    ₹1,120.10
    Prev close
    ₹1,119.10

    Key metrics

    P/E (TTM)
    24.8
    EPS (TTM)
    ₹44.87
    ROE (FY26)
    20.1%
    ROCE (latest year)
    21%
    Dividend yield
    0.09%

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +16.3%
    Profit 3Y CAGR
    +34.8%
    Revenue YoY (Jun 2026)
    +22.0%
    Profit YoY (Jun 2026)
    -34.9%
    Operating margin
    24.0%
    Net margin
    12.3%

    Revenue, profit & margin - quarterly

    Bars in ₹ crore (a loss shows red); line is operating margin

    Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Jun 20260 Cr2.5K Cr5.0K Cr7.5K Cr10.0K Cr0%9%18%27%36%
    • Revenue
    • Net profit
    • Operating margin

    Who owns the company

    Shareholding as of Jun 2026

    • Promoter
    • DII
    • FII
    • Public

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-9.0K Cr-4.5K Cr0 Cr4.5K Cr9.0K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%8%16%24%32%15%

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); line is debt-to-equity

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 20260 Cr7.0K Cr14.0K Cr21.0K Cr28.0K Cr0.0x0.2x0.4x0.6x0.8x
    • Equity
    • Debt
    • Debt / equity

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    Sales4,3694,5055,5346,2085,2375,2696,5286,5746,1236,8647,5878,017
    Expenses3,2233,4033,9034,1243,7763,8824,4024,4854,1075,0485,0336,088
    Operating Profit1,1461,1021,6302,0841,4611,3882,1262,0882,0161,8162,5541,929
    OPM %26%24%29%34%28%26%33%32%33%26%34%24%
    Other Income5360160636857-1391557526-26388
    Interest920353225327785101130123156
    Depreciation184195205215234229238238302360508555
    Profit before tax1,0069471,5501,9001,2711,1841,6721,9211,6871,3531,6601,307
    Tax %22%23%21%23%29%15%25%23%27%29%19%27%
    Net Profit8037901,2461,4829201,0261,2441,5211,2391,0231,341990
    EPS in Rs₹7.91₹7.80₹11.75₹14.11₹9.06₹10.17₹11.64₹14.58₹12.51₹10.36₹12.65₹9.42

    From company filings, updated 15 Sept 2026. Consolidated figures where the company reports them.Information only, not investment advice.

    Working-capital cycle

    Debtor Days73

    -3 days since Mar 2021

    Inventory Days282

    +55 days since Mar 2021

    Days Payable142

    -13 days since Mar 2021

    Cash Conversion Cycle212

    +64 days since Mar 2021

    Working Capital Days-40

    -34 days since Mar 2021

    Strengths, risks & growth

    In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

    Strengths

    • Company has delivered good profit growth of 18.8% CAGR over last 5 years

    Risks

    None flagged by the checklist.

    Compounded Sales Growth

    10 Years
    +11%
    5 Years
    +12%
    3 Years
    +16%
    TTM
    +21%

    Compounded Profit Growth

    10 Years
    +11%
    5 Years
    +19%
    3 Years
    +32%
    TTM
    +5%

    Stock Price CAGR

    10 Years
    +11%
    5 Years
    +15%
    3 Years
    +20%
    1 Year
    +8%

    Return on Equity

    10 Years
    +20%
    5 Years
    +21%
    3 Years
    +21%
    Last Year
    +21%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderSept 2025Dec 2025Mar 2026Jun 2026Change
    Promoter75.00%75.00%75.00%75.02%+0.02 pp
    FII7.34%7.06%6.95%6.89%-0.06 pp
    DII10.86%11.08%11.20%11.27%+0.07 pp
    Government0.00%0.00%0.00%0.00%0.00 pp
    Public6.81%6.86%6.86%6.83%-0.03 pp

    Filed with NSE for Jun 2026: promoters 75.01%, public 24.99% · XBRL filing

    Analysts & fund holdings

    58%
    58% recommend buy
    26 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E24.5 vs 46.4
    Sector P/B5.84
    Beta0.64

    Who holds the shares, quarter by quarter

    Mutual funds 5.12% (+0.24 pp)
    Mar 25
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    • Promoters75.0%
    • Foreign institutions6.9%
    • Mutual funds5.1%
    • Insurance6.0%
    • Other domestic institutions0.2%
    • Retail4.7%
    • Others2.1%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Parag Parikh Flexi Cap Fund2.02%1.52%+0.02 pp
    Kotak Flexi Cap Fund1.08%2.14%+0.07 pp
    HSBC Midcap Fund0.30%1.98%+1.98 pp
    ICICI Pru Large Cap Fund0.26%0.36%-0.03 pp
    Quant Mid Cap Fund0.21%2.98%+2.98 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

    Risk & trend

    From 248 daily sessions to 11 Sept 2026.

    Computed

    Risk

    Volatility (1Y)
    23.3%
    Downside volatility
    21.7%
    Worst 5% of days
    2.2%
    Average of that tail
    3.1%
    Max drawdown (1Y)
    17.9%
    Below its peak
    7.1%

    Against the market

    Beta vs Nifty 50
    0.67
    Correlation
    0.38
    Relative strength (3M)
    +4.8%
    ATR (14)
    2.7%

    Return

    Return 1M
    -4.1%
    Return 3M
    +2.8%
    Return 6M
    +21.2%
    Return 1Y
    —
    vs 200-day average
    +12.3%

    Momentum

    RSI (14)
    45.6
    MACD histogram
    -4.49
    Stochastic %K
    24.9
    ADX (14)
    14.4
    +DI / −DI
    17.3 / 21.3
    Money flow index
    56.7

    Participation

    Delivery (20d avg)
    53.3%
    vs its 60-day baseline
    +0.8 pts
    Volume vs 20-day
    -0.5σ
    Close vs day's VWAP
    -0.3%
    52-week position
    75 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Jun 2026.

    Computed

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      Not available — not reported in this filing

      Dividend - Re 1 Per Share

      24 Jul 2026
      ex-date
    • buyback
      Not available — not reported in this filing

      Buy Back

      29 May 2026
      ex-date
    • dividend
      ₹11.00

      Dividend - Rs 11 Per Share

      25 Jul 2025
      ex-date
    • dividend
      ₹3.00

      Dividend - Rs 3 Per Share

      26 Jul 2024
      ex-date
    • buyback
      Not available — not reported in this filing

      Buy Back

      23 Feb 2024
      ex-date
    • dividend
      ₹6.00

      Dividend - Rs 6 Per Share

      28 Jul 2023
      ex-date
    • dividend
      ₹2.50

      Dividend - Rs 2.50 Per Share

      28 Jul 2022
      ex-date
    • buyback
      Not available — not reported in this filing

      Buyback

      1 Jun 2022
      ex-date
    • dividend
      ₹3.50

      Annual General Meeting/Dividend - Rs 3.50 Per Share

      28 Jul 2021
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      12 Aug 2020
      ex-date
    • dividend
      ₹3.50

      Interim Dividend - Rs 3.50 Per Share

      23 Mar 2020
      ex-date
    • dividend
      ₹3.50

      Annual General Meeting/Dividend - Rs 3.50 Per Share

      25 Jul 2019
      ex-date
    • dividend
      ₹3.50

      Annual General Meeting/Dividend- Rs 3.50 Per Share (Purpose Revised)

      31 Jul 2018
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      27 Jul 2017
      ex-date
    • dividend
      ₹3.20

      Interim Dividend Rs 3.20 Per Share (Purpose Revised)

      16 Mar 2017
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      21 Jul 2016
      ex-date
    • dividend
      ₹3.20

      Interim Dividend - Rs 3.20/- Per Share

      17 Mar 2016
      ex-date
    • split
      Not available — not reported in this filing

      Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share

      6 Oct 2015
      ex-date
    • dividend
      ₹12.00

      Annual General Meeting/Dividend - Rs 12/- Per Share

      30 Jul 2015
      ex-date
    • dividend
      ₹9.00

      Annual General Meeting / Dividend - Rs 9/- Per Share

      17 Jul 2014
      ex-date

    Insider trades

    Last 12 months, market trades
    Net buying ₹9.6 L
    1 buys · ₹9.6 L
    0 sells · ₹0
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Jasodaben Babubhai Patel
    Promoter Group · Market Purchase
    		Buy1,000₹9.6 L17 Nov 2025

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Company announcements

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Credit Rating

    Credit Rating

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    The Company is going to participate in J.P. Morgan India Conference, 2026, on September 21, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper publication of Notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati editions, both on September 9, 2026.

    Company Update
    Settlement Agreement
    AGM/EGMPrice-sensitive
    Transcript Of The 31St Annual General Meeting

    Transcript of the 31st Annual General Meeting

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH.

    Company Update
    Incorporation Of A Wholly Owned Subsidiary In Gift City, Gandhinagar, Gujarat

    Incorporation of a wholly owned subsidiary in Gift City, Gandhinagar, Gujarat

    Company Update
    ESG Rating
    Company Update
    Disclosure Under SEBI (Prohibition Of Insider Trading) Regulations, 2015

    Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Investor Presentation

    Company Update
    ESG Rating
    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity.

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript of the post results earnings call held on August 11, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    The management of the Company will meet the investors in Singapore and Hong Kong between August 24, 2026, to August 26, 2026, in the form of a Non-Deal Roadshow (NDR).

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Update on Investor Conference

    Filed with BSE (scrip 532321); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Buybacks, open offers & rights issues

    Documents

    Annual reports

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 5 Feb 2025 (unaudited). View the source filing. Figures are as filed and are not investment advice.